Mark Fereshteh

Biography
Mark Fereshteh leads scientific strategy at Pathos, where he is building an AI-enabled oncology drug development model – grounding AI-driven insights in rigorous biology to improve patient selection and speed up high-confidence development decisions. A biotech executive with more than two decades of global leadership in oncology and immunology drug development, Mark has worked from early discovery through late-stage clinical development and regulatory approval. He has led or contributed to over 60 INDs across bispecific antibodies, antibody-drug conjugates, small molecules, and targeted protein degraders. He also played key roles in the development and approval of Opdivo, Yervoy, Sotyktu, EPKINLY, and TIVDAK. He was previously Vice President and Global Head of Precision Medicine and Diagnostics at Genmab, and earlier held senior leadership roles at Bristol Myers Squibb. He trained in cancer pharmacology and tumor biology at Georgetown University and did postdoctoral research at Duke University under Nobel Laureate Robert Lefkowitz.